News & Updates

Show Multimedia Only
Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma
Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma
17 Nov 2024

Patients with stage III melanoma show inconsistent use of adjuvant immunotherapy despite its survival benefits, according to a study.

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma
17 Nov 2024
Data support abrocitinib use beyond 2 years in adolescents with AD
Data support abrocitinib use beyond 2 years in adolescents with AD
05 Nov 2024 byMike Ng

Treating adolescents with moderate-to-severe AD with the JAK1-selective inhibitor abrocitinib has demonstrated an acceptable long-term safety profile and maintained efficacy for up to 112 weeks, as shown in an adolescent-focused post hoc analysis of 5 phase III trials

Data support abrocitinib use beyond 2 years in adolescents with AD
05 Nov 2024
Childhood eczema takes a toll on children’s and parents’ mental health
Childhood eczema takes a toll on children’s and parents’ mental health
04 Nov 2024 byKanas Chan

Eczema severity in children is associated with depression, anxiety and stress in both children with eczema and their parents, a cross-sectional study in Hong Kong has shown.

Childhood eczema takes a toll on children’s and parents’ mental health
04 Nov 2024